Search Form
First, enter a politician or zip code
Now, choose a category

Key Votes

HB 45 - Authorizes Terminally Ill Patients to Use Experimental Treatments - Pennsylvania Key Vote

Jay Costa, Jr. voted Yea (Passage With Amendment) on this Legislation.

Read statements Jay Costa, Jr. made in this general time period.

Timeline

Issues Related to HB 45

Stage Details

Legislation - Signed (Executive) -

Title: Authorizes Terminally Ill Patients to Use Experimental Treatments

Signed by Governor Tom Wolf
Legislation - Concurrence Vote Passed (House) (198-0) -

Title: Authorizes Terminally Ill Patients to Use Experimental Treatments

Legislation - Bill Passed With Amendment (Senate) (49-0) - (Key vote)
See How Your Politicians Voted

Title: Authorizes Terminally Ill Patients to Use Experimental Treatments

Vote Result
Yea Votes
Nay Votes
Vote Smart's Synopsis:

Vote to pass a bill that authorizes the use of investigational drugs, biological products and medical devices by eligible patients.

Highlights:

 

  • Authorizes drug manufacturers to provide an investigational drug, biological product, or medical device to an eligible patient either free of charge or in exchange for payment (Sec. 4).

  • Defines “eligible patient” as an individual who has met all of the following requirements (Sec. 3):

    • Has a terminal illness attested to by their physician;

    • Has been unable to participate in a clinical trial within 100 miles of their residence;

    • Has received a recommendation from their physician for an investigational drug, biological product, or medical device;

    • Has carefully considered all FDA approved treatment options;

    • Has given written, informed consent for use of the investigational drug, biological product, or medical device;

    • Has documentation from their physician that they meet the above requirements; and

    • Is not being treated as an inpatient in any hospital.

  • Defines “terminal illness” as a disease or condition that will soon result in death without life-sustaining procedures (Sec. 3).

  • Defines “investigational drug, biological product, or medical device” as a product that has successfully complete phase one of a clinical trial but has not been approved for general use by the FDA (Sec. 3).

  • Defines “written, informed consent” as a document signed by the patient and attested to by a physician and a witness that contains information including, but not limited to, the following (Sec. 3):

    • Clear identification of the specific investigational drug, biological product, or medical device the patient is seeking to use;

    • Description of the potentially best and worse outcomes of the treatment;

    • Information making clear that the patient’s insurer is not obligated to pay for the treatment; and

    • Indication that the patient may not be eligible for hospice care after treatment begins.

  • Specifies that healthcare providers may not be subject to criminal or civil liability, or be found to have committed unprofessional conduct, based on a recommendation for the use of an investigational drug, biological product, or medical device (Sec. 5).

  • Prohibits licensure boards from suspending or revoking a healthcare provider’s license based solely on such provider’s recommendation of an investigational drug, biological product, or medical device to an eligible patient (Sec. 5).

Legislation - Bill Passed (House) (193-0) -

Title: Authorizes Terminally Ill Patients to Use Experimental Treatments

Legislation - Introduced (House) -

Title: Authorizes Terminally Ill Patients to Use Experimental Treatments

Co-sponsors

Skip to top

Help us stay free for all your Fellow Americans

Just $5 from everyone reading this would do it.

Thank You!

You are about to be redirected to a secure checkout page.

Please note:

The total order amount will read $0.01. This is a card processor fee. Please know that a recurring donation of the amount and frequency that you selected will be processed and initiated tomorrow. You may see a one-time charge of $0.01 on your statement.

Continue to secure page »

Back to top